A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema by Komiya, Kosaku et al.
Virginia Commonwealth University
VCU Scholars Compass
Emergency Medicine Publications Dept. of Emergency Medicine
2017
A systematic review of diagnostic methods to
differentiate acute lung injury/acute respiratory
distress syndrome from cardiogenic pulmonary
edema
Kosaku Komiya
Virginia Commonwealth University, Oita University, Tenshindo Hetsugi Hospital, komiyakh1@oita-u.ac.jp
Tomohiro Akaba
Virginia Commonwealth University
Yuji Kozaki
Virginia Commonwealth University
Jun-ichi Kadota
Oita University
Bruce K. Rubin
Virginia Commonwealth University
Follow this and additional works at: https://scholarscompass.vcu.edu/emsa_pubs
Part of the Emergency Medicine Commons
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
This Article is brought to you for free and open access by the Dept. of Emergency Medicine at VCU Scholars Compass. It has been accepted for
inclusion in Emergency Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.
Downloaded from
https://scholarscompass.vcu.edu/emsa_pubs/11
RESEARCH Open Access
A systematic review of diagnostic methods
to differentiate acute lung injury/acute
respiratory distress syndrome from
cardiogenic pulmonary edema
Kosaku Komiya1,2,3*, Tomohiro Akaba1, Yuji Kozaki1, Jun-ichi Kadota2 and Bruce K. Rubin1
Abstract
Background: Discriminating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) from cardiogenic
pulmonary edema (CPE) is often challenging. This systematic review examines studies using biomarkers or images
to distinguish ALI/ARDS from CPE.
Methods: Three investigators independently identified studies designed to distinguish ALI/ARDS from CPE in
adults. Studies were identified from PubMed, and the Cochrane Central Register of Controlled Trials database
until July 3, 2017.
Results: Of 475 titles and abstracts screened, 38 full texts were selected for review, and we finally included 24
studies in this systematic review: 21 prospective observational studies, two retrospective observational studies,
and one retrospective combined with prospective study. These studies compared various biomarkers to differentiate
subjects with ALI/ARDS and in those with CPE, and 13 calculated the area under the receiver operator characteristic
curve (AUC). The most commonly studied biomarker (four studies) was brain natriuretic peptide (BNP) and the
discriminatory ability ranged from AUC 0.67–0.87 but the timing of measurement varied. Other potential biomarkers
or tools have been reported, but only as single studies.
Conclusions: There were no identified biomarkers or tools with high-quality evidence for differentiating ALI/ARDS
from CPE. Combining clinical criteria with validated biomarkers may improve the predictive accuracy.
Keywords: Heart failure, Acute respiratory failure, Pulmonary edema, Biomarkers
Background
Differentiating between cardiogenic pulmonary edema
(CPE) and acute lung injury (ALI) or acute respiratory
distress syndrome (ARDS) is challenging in the early
stages of illness [1]. The most widely accepted defin-
ition of ALI/ARDS had been based on the American-
European Consensus Conference (AECC) definition, of
acute onset respiratory failure with bilateral infiltrates
on chest radiograph, and pulmonary capillary wedge
pressure (PCWP) <18 mmHg, or absence of elevated
left atrial pressure [2]. However, pulmonary artery
catheterization is rarely used in clinical practice be-
cause clinical estimation of PCWP is invasive, costly,
and does not aid in the diagnosis of ALI/ARDS [3–7].
There were potential inconsistencies in this definition,
including a lack of explicit criteria for defining acute re-
spiratory failure, the sensitivity of the PaO2/FiO2 (P/F)
ratio to ventilator settings, poor reliability of the chest
radiograph criteria, and difficulties distinguishing ARDS
from CPE including that these diagnoses can coexist
[8, 9]. Based on these limitations, the Berlin definition
for ARDS was published in 2012 and is reported to
have better predictive validity for mortality, than this
earlier definition [8]. Pulmonary capillary wedge pres-
sure measurement was removed from this definition.
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Patients were presumed to have ARDS if they had re-
spiratory failure not fully explained by cardiac failure
or fluid overload as judged by the treating physician
using all available data.
In current practice and most clinical studies, ALI/
ARDS is usually differentiated from CPE by the clinical
circumstances and by physical findings, but this distinc-
tion is often made only by post hoc review after patient’
discharge or death, and is often based on the response
to therapy [10, 11]. The ARDS Clinical Trial Network
reported that fluid management to decrease cardio-
genic fluid retention and the effects of lung permeabil-
ity and edema, will shorten the duration of mechanical
ventilation and intensive care without increasing non-
pulmonary organ failure [12]. The differentiation be-
tween ALI/ARDS and CPE is important in order to
avoid delaying treatment of fluid retention and avoiding
unnecessary testing [13]. Several biomarkers to distin-
guish ALI/ARDS from CPE have been reported. The
aim of this systematic review was to review published
studies of potential biomarkers to distinguish ALI/
ARDS from CPE.
Methods
This systematic review was conducted using the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and the Meta-analysis of
Observational Studies in Epidemiology (MOOSE)
guidelines [14].
Search criteria
We included prospective or retrospective cohort studies
written in English, which evaluated biomarkers or im-
ages for differentiating ALI/ARDS from CPE in adults.
Studies that did not refer ALI/ARDS based on the
AECC or the Berlin definition were excluded from this
systematic review [2, 8]. We identified studies from the
PubMed database using the search terms: “acute lung
injury [All Fields] OR acute respiratory distress syn-
drome [All Fields] OR pneumonia [All Fields] AND
cardiogenic pulmonary edema [All Fields] OR hydro-
static pulmonary edema [All Fields] OR ARDS diagnos-
tics [All Fields] OR decompensated heart failure [All
Fields]”, and from the Cochrane Central Register of
Controlled Trials database using the search terms:
“acute lung injury AND cardiogenic pulmonary edema”,
“acute respiratory distress syndrome AND cardiogenic
pulmonary edema”, and “pneumonia AND cardiogenic
pulmonary edema” (accessed on July 3, 2017). All in-
cluded studies focused on distinguishing “pure” ALI/
ARDS from “pure” CPE. Mixed cases were excluded
from analysis. Studies published only in abstract form
were excluded. Full texts of articles were further evalu-
ated by three investigators (KK, TA, and YK).
Data extraction
We extracted the following information from included
studies: study design, sample size, diagnostic methods of
ALI/ARDS or CPE, assessed markers, mean value of the
markers in ALI/ARDS or CPE, the area under the receiver
operator characteristic curve (AUC), and specificity and
sensitivity for ALI/ARDS or CPE at a cutoff.
Assessing risk of bias
The risk of bias in the included studies was assessed
according to the recommendations outlined in the
Cochrane Handbook for Systematic Reviews of Interven-
tions Version 5.1.0. and MOOSE guidelines for the fol-
lowing items: selection, performance, detection, attrition,
and publication bias [14]. Each study included in this re-
view was assessed for quality as good, moderate, or poor
based on biases using the modified Hayden’s criteria
[15], which included source population, sample size,
inclusion criteria, how to determine the final diagnosis
of ALI/ARDS or CPE, and analysis providing sufficient
presentation of data. Three investigators independently
determined the quality based on these points. Disagree-
ments among the investigators were resolved by review
of the assessments to reach consensus.
Results
Database search and characteristics of included studies
We identified 475 studies through PubMed and CENTRAL
databases, and then excluded 437 studies as the abstract
did not meet the inclusion criteria. We excluded 14 of
the remaining 38 records after retrieving and inspecting
the full text (Fig. 1).
We finally included 24 studies in this systematic re-
view: ten studies using systemic biomarkers which were
measured in plasma [the quality of these studies by the
modified Hayden’s criteria was, good (n = 6) [10, 16–20],
moderate (n = 1) [21], and poor (n = 3) [22–24]], and 11
studies using “lung-specific” biomarkers measured in
bronchoalveolar lavage (BAL) or pulmonary edema
fluid [quality was good (n = 2) [25, 26] and poor (n = 9)
[27–35]], three studies of chest ultrasonography or
computed tomography (CT) [good (n = 1) [36] and
moderate (n = 2) [37, 38]]. Most were reported as pro-
spective cohort studies but two studies were retrospect-
ive and one study combined a retrospective cohort with
a prospective cohort. These studies were published
from the USA (n = 10), Japan (n = 5), Germany (n = 2),
Australia (n = 2), China (n = 2), Italy (n = 1), Belgium
(n = 1), The Netherlands (n = 1), Taiwan (n = 1), and
Switzerland (n = 1).
Sixteen studies diagnosed either ALI/ARDS or CPE
using clinical information [10, 16–18, 21, 22, 24–27, 29,
30, 34, 36–38], and in eight studies the final diagnosis
was confirmed by at least two independent reviewers
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[10, 16–18, 21, 26, 36, 37]. Six studies [19, 20, 23, 32, 33,
35] used the results of PCWP by pulmonary artery
catheterization and two studies used the edema fluid
protein/plasma protein ratio to differentiate ALI/ARDS
from CPE [28, 31].
Systemic biomarkers
Nine of ten studies that evaluated systemic markers to
distinguish ALI/ARDS from CPE assessed predictive
power using AUC. Brain natriuretic peptide (BNP) was
the most commonly assessed biomarker (Table 1). The
discriminatory ability to differentiate CPE from ARDS
varied among four studies with AUC, 0.67–0.83. The
levels of plasma CRP in patients with ALI/ARDS were
significantly higher than those with CPE [18, 33]. In
these studies, subjects thought to have both ALI/ARDS
and CPE were explicitly excluded from the analysis.
Komiya and colleagues showed that when C-reactive
protein was used to differentiate CPE from ALI/ARDS,
the AUC was as good as BNP, and the AUC when the
combination of BNP and CRP was used to differentiate
CPE from ALI/ARDS was significantly higher than either
BNP or CRP alone.
The plasma soluble suppression of tumorigenicity-2
[20], heparin-binding protein [39], and copeptin [16]
were evaluated in single studies that showed high pre-
dictive value for differentiating ALI/ARDS from CPE.
Arif and colleagues reported that pulmonary leak
index was significantly higher in ARDS than in CPE
patients and the AUC for ARDS was 0.98 for transfer-
rin, 0.95 for total protein, and 0.80 for albumin levels
in plasma [22]. Other studies compared mean value of
mucin-associated antigen in serum, or arteriovenous
differences in lactate between ALI/ARDS and CPE but
the sample size for each of these studies was small,
and the methods used as the standard for diagnosis
were unclear.
Lung biomarkers
Only one of the 11 studies that evaluated “lung-specific”
biomarkers used AUC to evaluate their ability to distin-
guish ALI/ARDS from CPE (Table 2). Ware and col-
leagues showed that the fluid-to-plasma protein ratio
had a high AUC and good sensitivity and specificity for
differentiating ALI from CPE, and that a fluid to plasma
ratio >0.65 was associated with higher mortality and
more days requiring mechanical ventilation [25]. Schutte
and colleagues reported that the protein concentration
in BALF from ALI/ARDS subjects was higher than in
CPE [33]. In two studies, surfactant apoprotein (SP)-A
was significantly greater in BALF from subjects with
CPE compared to those with ALI/ARDS [32, 35].
Laminin gamma-2 fragments are parts of laminin-5,
which is a cellular adhesion molecule expressed solely
Records identified through database 
searching from PubMed and CENTRAL.
(n = 475)
Full-text articles assessed for eligibility
(n = 38)
Studies with eligible data
(n = 24)
Systemic marker (n = 10)
Local marker (n = 11)
Image (n = 3)
Excluded (n = 437)
Not written in English (n = 85)
Review without data (n = 96)
Case report (n = 29)
Letter or statement (n = 22)
Mismatched sample (n = 84)
Mismatched intervention / outcomes (n = 84)
Not a clinical trial (n = 18)
Duplicate or overlapping data (n = 17)
Mixed cases combined with ALI/ARDS group (n = 2)
Excluded (n = 14)
No diagnostic criteria listed for ALI/ARDS or CPE (n = 8)
No description of mean value of marker or score (n = 6)
Fig. 1 Flow diagram of the study selection
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by epithelium, and promotes epithelial cell migration
and repair of injured epithelium [40]. The concentra-
tion of these fragments in epithelial lining fluid from
subjects with ALI/ARDS was significantly higher than
those with CPE, and the concentration of laminin
gamma-2 fragments at 5 days after onset also was as-
sociated with mortality [27].
Imaging studies
Copetti and colleagues evaluated the ability of chest
ultrasound to detect characteristic signs of ALI/ARDS vs
CPE [38] (Table 3). During normal breathing, sonog-
raphy can detect the lung moving or “sliding” along the
pleura, but this sliding is impaired when there are in-
flammatory adhesions. While subjectively, normal lung
sliding is seen in subjects with CPE, it is absent or de-
creased in subjects with ALI/ARDS. “B lines” on chest
sonography (distinct from Kerly B lines on plain radiog-
raphy, and previously called comet-tail artifacts), are
generated from the thickened interlobular septa (e.g.,
seen in interstitial edema) at the lung wall interface [41].
Sekiguchi and colleagues reported that a higher “B-line
ratio” (proportion of chest zones with positive B lines
relative to all zones examined) was specific for the diag-
nosis of CPE, and that findings of a left-sided pleural
effusion >20 mm, moderate or severe left ventricle dys-
function, and minimal diameter of inferior vena cava
>23 mm were helpful to distinguish CPE from ALI/
ARDS using a derived, simplified prediction score as
shown in Table 3 [36]. Some features on chest CT were
reported to better differentiate ARDS from CPE. Small
ill-defined opacities, defined as patchy areas of ground-
glass attenuation or airspace consolidation, and left-
dominant pleural effusion had high specificity for ALI/
ARDS in a single-center retrospective study [37].
Discussion
We systematically reviewed serum and pulmonary bio-
markers, and imaging used to differentiate ALI/ARDS
from CPE. BNP, released from ventricular cardiomyo-
cytes in response to both ventricle volume expansion
and pressure overload, was the most commonly evalu-
ated biomarker; but the predictive ability was variable.
While two studies measured BNP levels early in the
clinical presentation, and these showed a good discrim-
inatory ability [18, 19], other studies allowed BNP to be
tested up to 3 hours (IQR 0.5–14) [10] or 48 hours
after presentation and these were less able to distin-
guish ARDS/ALI from CPE [21]. BNP is known to de-
crease after treatment for heart failure [42] and this
could explain the higher discriminatory ability before
starting treatment. Replicate and prospective studies
with consistent timing of measurements are required in
order to improve the quality of evidence.
As well, the subjects in the study by Levitt [21] were
younger than in the other studies [10, 18, 19] and in the
younger subjects BNP was a less sensitive biomarker. Be-
cause elderly patients may respond less well to diuretics,
ACE inhibitors, and inotropic agents compared to youn-
ger patients [43], the younger patients may also respond
to treatment more rapidly. Renal failure often accom-
panies severe sepsis and ARDS and this can increase
BNP despite normal cardiac function [44]. Due to these
different patient characteristics in each study, we did not
collect these raw data to combine for a meta-analysis.
CRP is widely used as a marker of systemic inflamma-
tion, and in one study by the authors of this review;
AUC when CRP was used to differentiate ALI/ARDS
from CPE was as good as when BNP was used [18].
While BNP levels can increase in some conditions such
as renal failure or sepsis despite normal cardiac function
[44], CRP is not directly influenced by cardiac function.
CRP combined with BNP may have greater discrimin-
atory ability than either BNP or CRP alone [18].
Plasma soluble suppression of tumorigenicity-2, an IL-
1 receptor family member which is a mediator of inflam-
mation and immunity, showed excellent discrimination
[20]. Heparin-binding protein is an antimicrobial protein
stored in neutrophil granules, and it induces cytoskeletal
rearrangement of endothelial cells, which leads to break-
down of cell barriers and an increase in macromolecular
efflux [39]. Copeptin, the C-terminal portion of the ar-
ginine vasopressin precursor, is secreted together with
arginine vasopressin precursor from the neurohypophy-
sis. This secretion is thought to reflect the inflammatory
cytokine response and the presence of hemodynamic
and osmoregulatory disturbances [45, 46]. These bio-
markers appeared to be robust in discriminating ALI/
ARDS from CPE in single studies; so validation in repli-
cate studies will be necessary.
Sample size in each study for lung-specific biomarkers
was small compared with studies of serum biomarkers,
and airway sampling by BAL may be difficult in the
emergency department setting. When pulmonary edema
is present, pulmonary edema fluid can be obtained by
inserting a suction catheter into an endotracheal tube
until frothy fluid is obtained by suctioning [25]. The pul-
monary edema fluid-to-plasma protein ratio has been
studied for decades as a tool to differentiate pulmonary
permeability edema from hydrostatic edema [47].
Combining cardiac and thoracic ultrasonography
could help to determine the cause of acute pulmonary
edema [36]. However, these techniques are operator-skill
dependent. Chest CT may be better at discriminating
ALI/ARDS from CPE than chest radiography; although
CT is rarely performed for acute respiratory failure in
the emergency department setting. Milne and colleagues
performed an independent two-observer study of chest
Komiya et al. Critical Care  (2017) 21:228 Page 6 of 10
Ta
b
le
3
Im
ag
in
g
to
di
ffe
re
nt
ia
te
A
LI
/A
RD
S
fro
m
C
PE
St
ud
y
D
es
ig
n
N
o.
of
A
LI
/
A
RD
S
vs
C
PE
M
ar
ke
r
Ti
m
in
g
of
m
ea
su
re
m
en
t
A
U
C
95
%
C
I
C
ut
of
f
Fo
r
Sp
ec
ifi
ci
ty
(%
)
Se
ns
iti
vi
ty
(%
)
Se
ki
gu
ch
i,
20
15
**
*
Pr
os
pe
ct
iv
e
42
vs
59
C
om
bi
ne
d
ca
rd
ia
c
an
d
th
or
ac
ic
ul
tr
as
on
og
ra
ph
y
W
ith
in
6
h
of
di
ag
no
si
s
N
um
be
r
of
ch
es
t
zo
ne
s
w
ith
po
si
tiv
e
B-
lin
es
0.
82
0.
75
–0
.8
8
3
M
is
ce
lla
ne
ou
s
ca
us
es
42
(9
5%
C
I3
2–
52
)
10
0
(9
5%
C
I8
9–
10
0)
Sc
or
e;
le
ft
pl
eu
ra
le
ffu
si
on
>
20
m
m
(+
4)
,M
od
er
at
e
or
se
ve
re
LV
dy
sf
un
ct
io
n
(+
3)
,a
nd
IV
C
m
in
im
al
di
am
et
er
<
=
23
m
m
(-2
).
0.
79
0.
70
–0
.8
7
>
=
6
C
PE
98
(9
5%
C
I8
7–
10
0)
39
(9
5%
C
I2
6–
52
)
Ko
m
iy
a,
20
13
**
Re
tr
os
pe
ct
iv
e
20
vs
41
C
he
st
C
T
W
ith
in
2
ho
ur
s
of
ar
riv
al
at
ED
U
pp
er
-lo
be
-p
re
do
m
in
an
t
G
G
A
C
PE
95
48
.8
C
en
tr
al
-p
re
do
m
in
an
t
G
G
A
C
PE
90
58
.5
C
en
tr
al
ai
rs
pa
ce
co
ns
ol
id
at
io
n
C
PE
90
56
.1
Sm
al
li
ll-
de
fin
ed
op
ac
iti
es
A
RD
S
87
.8
35
Le
ft-
do
m
in
an
t
pl
eu
ra
le
ffu
si
on
A
RD
S
95
.1
25
C
op
et
ti,
20
08
**
Pr
os
pe
ct
iv
e
18
vs
40
C
he
st
so
no
gr
ap
hy
N
ot
st
at
ed
A
lv
eo
la
r-
in
te
rs
tit
ia
ls
yn
dr
om
e
A
LI
/A
RD
S
0
10
0
C
PE
0
10
0
Pl
eu
ra
ll
in
e
ab
no
rm
al
iti
es
A
LI
/A
RD
S
45
10
0
C
PE
0
25
Re
du
ct
io
n
or
ab
se
nc
e
of
lu
ng
sl
id
in
g
A
LI
/A
RD
S
10
0
10
0
C
PE
0
0
Sp
ar
ed
ar
ea
s
A
LI
/A
RD
S
10
0
10
0
C
PE
0
0
C
on
so
lid
at
io
ns
A
LI
/A
RD
S
10
0
83
.3
C
PE
0
0
Pl
eu
ra
le
ffu
si
on
A
LI
/A
RD
S
5
66
.6
C
PE
33
.3
95
Lu
ng
pu
ls
e
A
LI
/A
RD
S
10
0
50
C
PE
50
0
A
LI
ac
ut
e
lu
ng
in
ju
ry
,A
RD
S
ac
ut
e
re
sp
ira
to
ry
di
st
re
ss
sy
nd
ro
m
e,
A
U
C
ar
ea
un
de
r
th
e
cu
rv
e,
B-
lin
es
ve
rt
ic
al
na
rr
ow
ba
se
d
lin
es
ar
is
in
g
fr
om
th
e
pl
eu
ra
ll
in
e
to
th
e
ed
ge
of
th
e
ul
tr
as
ou
nd
sc
re
en
,C
T
co
m
pu
te
d
to
m
og
ra
ph
y,
CP
E
ca
rd
io
ge
ni
c
pu
lm
on
ar
y
ed
em
a,
G
G
A
gr
ou
nd
-g
la
ss
at
te
nu
at
io
n,
ED
em
er
ge
nc
y
de
pa
rt
m
en
t,
IV
C
in
fe
rio
r
ve
na
ca
va
,L
V
le
ft
ve
nt
ric
ul
ar
**
*G
oo
d,
or
**
m
od
er
at
e
qu
al
ity
as
se
ss
ed
ba
se
d
on
bi
as
es
us
in
g
th
e
m
od
ifi
ed
H
ay
de
n’
s
cr
ite
ria
M
is
ce
lla
ne
ou
s
in
cl
ud
in
g
un
ila
te
ra
lp
ne
um
on
ia
,a
te
le
ct
as
is
,C
O
PD
,p
ul
m
on
ar
y
em
bo
lis
m
or
pn
eu
m
ot
ho
ra
x
Komiya et al. Critical Care  (2017) 21:228 Page 7 of 10
radiographs from 61 subjects with cardiac disease, and
28 with capillary permeability edema, not described as
ALI or ARDS [48]. The overall accuracy for distinguish-
ing capillary permeability edema from cardiac edema
was 91%. Another study reported that 87% of subjects
with hydrostatic edema but only 60% of those with
increased permeability edema were correctly identified
in critical ill patients [49]. It is controversial if chest
radiography can be recommended to differentiate the
type of pulmonary edema.
A limitation of studies focusing on biomarkers or im-
ages for discriminating ALI/ARDS from CPE is that
these can coexist [8]. Some degree of hydrostatic edema
is present in many cases of ALI/ARDS, in fact the
pulmonary capillary wedge pressure is reported to be
elevated in 30% of ARDS patients [12]. Schmickl and
colleagues developed a decision support algorithm to
distinguish CPE from ARDS based on clinical data [11].
However, while all studies included in this systematic
review specifically excluded mixed cases of ALI/ARDS
with CPE, these authors included these cases in the
ALI/ARDS group. Protein biomarkers such as BNP
showed no statistically significant difference when com-
paring “pure” CPE with serum from subjects with ALI/
ARDS both with and without CPE. BNP levels were ele-
vated for both ALI/ARDS with and without CPE and
pure CPE (708 pg/mL vs 749 pg/mL; p = 0.18). Strict
fluid management that addresses cardiogenic pulmon-
ary edema and pulmonary permeability edema increases
ventilator-free days [12]. This suggests that biomarkers
like BNP could be useful for differentiating CPE from
ALI/ARDS and for initiating fluid restriction and di-
uretics early to decrease the risk of CPE.
We identified that some biomarkers, e.g., soluble sup-
pression of tumorigencity-2, BNP plus CRP, heparin-
binding protein, and plasma transferrin had high AUCs
for differentiating ALI/ARDS from CPE, but these
were each only assessed in a single study. All studies
compared the biomarker measurement to the clinical
diagnosis, but no study compared accuracy of the clin-
ical diagnosis alone to that of clinical diagnosis plus
biomarkers. Since ALI/ARDS and CPE can certainly
co-exist, biomarkers need to be considered to evaluate
the relative role of CPE in contributing to the morbidity
of ALI/ARDS.
Because there are no accepted criteria for differenti-
ating CPE from ALI/ARDS at the time of clinical pres-
entation, for these studies, the decision to classify as
ALI/ARDS versus CPE was made by clinical expert(s)
reviewing clinical information and response to therapy
including diuretics. The fundamental questions are: are
biomarkers measured at clinical presentation more reli-
able (and accessible) than post hoc experts’ opinion in
differentiating these conditions and can biomarkers
identify patients who should have therapy for both con-
ditions (coexisting). Neither question was answered by
this systematic review, largely because there is no true
gold standard for distinguishing ARDS/ALI from CPE.
Given this limitation we understood that the purpose
of this review was to identify potential biomarkers that
would most closely correlate with expert clinical judge-
ment, which was often post hoc – after the diagnosis
became clear. If these biomarkers could be then used
for earlier detection and intervention, as suggested by
the studies showing that BNP appeared to be most use-
ful when measured at the time of presentation in the
emergency department and before initiating therapy,
this may allow guidance of appropriate intervention be-
fore such time that the clinical differentiation is clear.
Conclusions
We found that there were no identified biomarkers or
tools with high-quality evidence for differentiating ALI/
ARDS from CPE. Because there is no objective “gold
standard” for diagnosing ALI/ARDS or CPE, a clear
distinction between ALI/ARDS and CPE may not have
been possible in any of these reported studies. The
eventual diagnosis was determined by post hoc expert
review, blinded to target marker. These limitations pose
an obstacle to developing a reliable method to differen-
tiate these disorders. However, differentiating the cause
of pulmonary edema is important because the therapy
of ALI/ARDS and CPE are fundamentally different.
Although fluid restriction might be used to treat both
CPE and ARDS/ALI, early recognition of ALI/ARDS
allows an emphasis on lung-protective ventilation and
in the treatment of the underlying cause of the ARDS
whilst recognition of CPE may lead to the appropriate
use of diuretics, inotropic therapy, and afterload reduc-
tion. Combining clinical criteria with validated bio-
markers may improve the predictive accuracy and
improve the outcomes of ALI/ARDS even it co-exists
with CPE.
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